Axsome Therapeutics AXSM Tax on Share Settlement
Tax on Share Settlement at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's tax on share settlement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's tax on share settlement?
- Axsome Therapeutics (AXSM) reported tax on share settlement of $9.3M in Q1 2026.
- How has Axsome Therapeutics's tax on share settlement changed year-over-year?
- Axsome Therapeutics's tax on share settlement increased by 114.5% year-over-year, from $4.34M to $9.3M.
- What is the long-term trend for Axsome Therapeutics's tax on share settlement?
- Over 3 years (2022 to 2025), Axsome Therapeutics's tax on share settlement has grown at a 137.3% compound annual growth rate (CAGR), from $532K to $7.11M.
- What does tax on share settlement mean?
- Cash paid to cover taxes for employees when their stock awards vest.
- How do you interpret tax on share settlement?
- Higher payments correlate with higher equity vesting activity and potentially higher stock-based compensation expense.
- How does tax on share settlement compare across companies?
- Standard for companies with significant stock-based compensation; varies with vesting schedules and share price.